Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Crescenta Biosciences is active in the Biotechnology & Pharmaceuticals technology area with 3 pending office actions currently on record. These actions are distributed among 3 distinct examiners, showing that the company's patent applications are being evaluated across a variety of technical perspectives within the pharmaceutical sector.
The prosecution workload is further spread across 3 distinct art units. BELL, SARA ELIZABETH is the busiest examiner for the portfolio, currently managing 1 pending office action. Since each of the 3 distinct examiners is responsible for exactly 1 pending office action, the workload is balanced, preventing any single examiner from having an outsized impact on the company's overall strategy.
With 3 distinct art units involved, the company must navigate multiple sets of examination criteria. Practitioners should be prepared for different procedural approaches across these 3 units. The presence of 3 pending office actions across 3 distinct examiners highlights the need for a coordinated effort to maintain a unified portfolio strategy in the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BELL, SARA ELIZABETH | 1 | 68.8% | +38.2% |
| STOCKTON, LAURA LYNNE | 1 | 75.2% | +33.7% |
| WILSON, JERICA KATLYNN | 1 | 61.4% | +39.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17793670 | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF | STOCKTON, LAURA LYNNE | — |
| 17566692 | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF FOR THE TREATMENT OF VIRAL DISEASES | WILSON, JERICA KATLYNN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18014981 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | BELL, SARA ELIZABETH | — |
| 17793670 | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF | STOCKTON, LAURA LYNNE | — |
| 17566692 | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF FOR THE TREATMENT OF VIRAL DISEASES | WILSON, JERICA KATLYNN | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1626 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18014981 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | BELL, SARA ELIZABETH | 1625 | §103§112DP | Non-Final OA | — | Pending | Jan 06, 2023 |
| 17793670 | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF | STOCKTON, LAURA LYNNE | 1626 | §102§112Other | Non-Final OA | — | Pending | Jul 19, 2022 |
| 17566692 | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF FOR THE TREATMENT OF VIRAL DISEASES | WILSON, JERICA KATLYNN | 1621 | §103§112 | Final Rejection | — | Pending | Dec 31, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial